Serrapeptase for Chronic Bronchitis

Verdict: Contradicted by stronger evidence; does not work

Serrapeptase is not an evidence-based treatment for chronic bronchitis: the only positive data come from a single tiny open-label trial, while the strongest study available was negative and led the original manufacturer to pull the drug from the market.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

The entire positive case rests on one small open-label trial (Nakamura 2003, PMID 12911824, n=29) that used no placebo and no blinding. It reported less viscous sputum, fewer coughs, and better mucociliary clearance (index 13.3 to 24.4), but that design is highly vulnerable to placebo effect and observer bias, so the signal is weak. A 2013 systematic review of 24 efficacy studies (PMID 23380245) judged the whole serratiopeptidase evidence base to be of poor methodological quality.

Decisively, the best-quality data are negative. A 2020 review (PMID 33134103) documents that in 2011 the original maker, Takeda, voluntarily withdrew Danzen (serrapeptase) in Japan after a larger double-blind, placebo-controlled trial showed no benefit over placebo for difficult expectoration; Singapore phased it out for lack of substantive evidence. When the strongest study is negative and only a low-quality trial is positive, the honest conclusion is that it does not work.

Regulators and clinics reinforce this. The US FDA has never approved it and treats disease claims as marketing an unapproved drug, while the UK and EU classify serrapeptase as an unauthorised novel food that is illegal to sell as a supplement. No major respiratory body or clinic (Mayo, Cleveland Clinic, Harvard, ATS/CHEST) endorses it for airway mucus, and rare drug-induced lung injury reports add caution.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.33
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
82%
Highly consistent evidence
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.20
L3 MechanismPlausibility
0.25
L11 AI re-checkIndependent read
0.30
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.327
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease
PMID: 12911824 2003 RCT (open-label) n = 29
Finding: In the serrapeptase group, morning sputum weight, percentage solid component, sputum viscosity and elasticity, sputum neutrophil count, frequency of coughing and frequency of expectoration significantly decreased; mean mucociliary transportability index increased from 13.3 to 24.4. No placebo control and no blinding.
🟠 Limited quality Effect size: Mucociliary transportability index 13.3 to 24.4; sputum viscoelasticity and neutrophil count reduced (open-label, not blinded)
View on PubMed
Serratiopeptidase: a systematic review of the existing evidence
PMID: 23380245 2013 系統性回顧
Finding: Of 24 clinical efficacy studies meeting inclusion criteria, the evidence for serratiopeptidase as an anti-inflammatory, analgesic and mucolytic agent is based on studies of poor methodology (few RCTs, small samples, weak controls). For respiratory disease the review notes claimed improvements in mucociliary transportability and sputum viscoelasticity but flags the evidence base as inadequate; in one comparative study Seaprose S outperformed serratiopeptidase for difficulty expectorating.
🟠 Limited quality Effect size: No pooled effect estimate; review concludes evidence is of poor methodological quality
View on PubMed
Serratiopeptidase: Insights into the therapeutic applications
PMID: 33134103 2020 Other
Finding: Review documents that in 2011 Takeda (the proprietor) voluntarily withdrew serratiopeptidase (Danzen) from the Japanese market after double-blind trials failed to show superiority over placebo as an expectorant and anti-inflammatory agent, and that Singapore phased it out citing lack of substantive scientific evidence. Concludes the reported therapeutic impact needs to be backed by more rigorous scientific data.
🟠 Limited quality Effect size: Not an efficacy study; documents regulatory withdrawal for lack of proven efficacy
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Products may be legally marketed as dietary supplements if claims about diagnosis, cure, mitigation, treatment, or prevention are removed from promotional materials and the products otherwise comply with all applicable provisions of the Act and FDA regulations. source↗
L4b EU EFSA
Against
L4c UK NHS
Against
Serratiopeptidase is an unauthorised novel food, and it is illegal for businesses to sell serrapeptase as a food supplement for human consumption in the EU and UK because it is an unauthorised novel food. source↗
L4d TW TFDA / 衛福部
Neutral
適應症:手術後及外傷後之消炎、副鼻腔炎、膀胱炎、副睪丸炎、智齒周圍炎、齒槽膿瘍之消炎、支氣管炎。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-respiratory-bronchitis-INT-serrapeptase-001 繁體中文版 →